| 2026-08-21 16:30 |
8-K |
["3.03", "5.03", "7.01", "9.01"] |
other |
0.05
|
Reverse stock split (1:7) announcement; routine corporate action unrelated to M&A. |
SEC · detail |
| 2026-07-22 08:35 |
8-K |
["1.01", "8.01", "9.01"] |
material agreement |
0.05
|
Research collaboration agreement with Bayer for radium supply; no M&A or transaction indicators. |
SEC · detail |
| 2026-07-15 08:30 |
8-K |
["8.01", "9.01"] |
other |
0.05
|
Clinical trial safety data announcement; no M&A or strategic transaction signals present. |
SEC · detail |
| 2026-06-30 17:19 |
8-K |
["5.07"] |
other |
0.05
|
Routine annual stockholder meeting results; no M&A-related activity indicated. |
SEC · detail |
| 2026-06-04 08:00 |
8-K |
["8.01", "9.01"] |
other |
0.05
|
Routine press release on H1 2026 achievements; no M&A or transaction signals. |
SEC · detail |
| 2026-05-18 08:31 |
8-K |
["8.01", "9.01"] |
other |
0.05
|
Routine 8-K disclosing investor presentation at conference; no M&A signals detected. |
SEC · detail |